239 related articles for article (PubMed ID: 25701988)
41. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
42. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
Dong M; Mizuno T; Vinks AA
Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
[TBL] [Abstract][Full Text] [Related]
43. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
44. Intensive hydroxyurea dosing in very young children with sickle cell anemia.
Wang WC; Brown RC; McNaull MA; Rogers ZR; Barton M; Dua MR; Hankins JS; Gossett J; Richardson J; Porter JS; Kang G; Estepp JH
Blood Adv; 2023 Nov; 7(22):6931-6935. PubMed ID: 37695741
[No Abstract] [Full Text] [Related]
45. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
Stettler N; McKiernan CM; Melin CQ; Adejoro OO; Walczak NB
JAMA; 2015 Apr; 313(16):1671-2. PubMed ID: 25919532
[No Abstract] [Full Text] [Related]
46. Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia.
McLaren A; Klingel M; Behera S; Odame I; Kirby-Allen M; Grasemann H
Am J Respir Crit Care Med; 2017 Mar; 195(5):689-691. PubMed ID: 28248149
[No Abstract] [Full Text] [Related]
47. Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Lê PQ; Ferster A; Cotton F; Vertongen F; Vermylen C; Vanderfaeillie A; Dedeken L; Heijmans C; Ketelslegers O; Dresse MF; Gulbis B
Med Trop (Mars); 2010 Dec; 70(5-6):467-70. PubMed ID: 21516988
[TBL] [Abstract][Full Text] [Related]
48. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
49. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
50. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
Lobo CL; Pinto JF; Nascimento EM; Moura PG; Cardoso GP; Hankins JS
Br J Haematol; 2013 Jun; 161(6):852-60. PubMed ID: 23590693
[TBL] [Abstract][Full Text] [Related]
51. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
52. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
53. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P
Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960
[No Abstract] [Full Text] [Related]
54. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
55. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
Joseph L; Jean C; Manceau S; Chalas C; Arnaud C; Kamdem A; Pondarré C; Habibi A; Bernaudin F; Allali S; de Montalembert M; Boutonnat-Faucher B; Arlet JB; Koehl B; Cavazzana M; Ribeil JA; Lionnet F; Berthaut I; Brousse V
Blood; 2021 Feb; 137(6):826-829. PubMed ID: 32976551
[TBL] [Abstract][Full Text] [Related]
56. Social media discussions provide new insight about perceptions of hydroxyurea in the sickle cell community.
Walker AL; Gaydos LM; Farzan R; De Castro L; Jonassaint C
Am J Hematol; 2019 May; 94(5):E134-E136. PubMed ID: 30734364
[No Abstract] [Full Text] [Related]
57. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
Mulaku M; Opiyo N; Karumbi J; Kitonyi G; Thoithi G; English M
Arch Dis Child; 2013 Nov; 98(11):908-14. PubMed ID: 23995076
[TBL] [Abstract][Full Text] [Related]
58. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
[No Abstract] [Full Text] [Related]
59. Impact of hydroxyurea on clinical events in the BABY HUG trial.
Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
[TBL] [Abstract][Full Text] [Related]
60. The rationale for using hydroxycarbamide in the treatment of sickle cell disease.
Rees DC
Haematologica; 2011 Apr; 96(4):488-91. PubMed ID: 21454878
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
